Celldex Therapeutics (CLDX) Other Non-Current Assets (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly Other Non-Current Assets came in at $15.4 million in Q1 2026, up 48.28% year-on-year from $10.4 million in Q1 2025, and up 15.54% quarter-over-quarter from $13.4 million in Q4 2025.
Celldex Therapeutics (CLDX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $15.4 million for Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 48.28% year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $15.4 million, a 48.28% increase from a year earlier, with the FY2025 full-year figure at $13.4 million, up 37.05% from the prior year.
- Other Non-Current Assets rose to $15.4 million in Q1 2026 per CLDX's latest filing, from $13.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $15.4 million in Q1 2026 and bottomed at $104000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $107000.0 (2023), against an average of $4.6 million.
- Biggest YoY gain for Other Non-Current Assets was 9628.04% in 2025; the steepest drop was 3.93% in 2025.
- Year by year, Other Non-Current Assets stood at $104000.0 in 2022, then climbed by 2.88% to $107000.0 in 2023, then jumped by 9009.35% to $9.7 million in 2024, then jumped by 37.05% to $13.4 million in 2025, then rose by 15.54% to $15.4 million in 2026.
- Per Business Quant, the three latest CLDX Other Non-Current Assets figures stand at $15.4 million (Q1 2026), $13.4 million (Q4 2025), and $9.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn | 15.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.43 Mn |
| Dec 31, 2025 | 13.36 Mn |
| Sep 30, 2025 | 9.36 Mn |
| Jun 30, 2025 | 9.30 Mn |
| Mar 31, 2025 | 10.41 Mn |
| Dec 31, 2024 | 9.75 Mn |
| Sep 30, 2024 | 9.75 Mn |
| Jun 30, 2024 | 107,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | 107,000.00 |
| Jun 30, 2023 | 107,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Dec 31, 2022 | 104,000.00 |
| Sep 30, 2022 | 104,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 104,000.00 |
| Dec 31, 2021 | 104,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | 41,000.00 |